Association of Body Fluid Distribution with Obstructive Sleep Apnea in Pregnant Women with Body Mass Index ≥ 40 Kg/m2
1 other identifier
observational
52
1 country
1
Brief Summary
Obstructive Sleep apnea (OSA) is a common and underdiagnosed condition in obese pregnant women with serious and life-threatening complications to the mother and baby. The investiators propose that a non-invasive method may be used to detect patients at risk of OSA, giving these women access to the necessary treatment to treat this condition. The method is a estimation of body water, which has been shown to be linked to OSA in the non-pregnant population. Body water is estimated by applying surface electrodes to a participant who is lying down by measuring bioimpedance through body tissues by applying a tiny current between the electrodes. The electrical stimulation is not felt by the participant and has no negative effects on mother or baby.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 26, 2019
CompletedStudy Start
First participant enrolled
December 2, 2019
CompletedFirst Posted
Study publicly available on registry
December 5, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedFebruary 26, 2025
February 1, 2025
6 years
November 26, 2019
February 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Presence of sleep apnea
The diagnosis of sleep apnea will be made using apnea hypopnea index (AHI). A diagnosis of OSA is present if a person has an AHI ≥5/hour.
12 hours
Secondary Outcomes (10)
Total body water measurement
Following consent, this measurement will be done, and will take approximately 30 minutes
Mallampati score
Done during initial exam following consent, this exam will take 1-2 minutes
Thyromental distance (cm)
Done during initial exam following consent, this exam will take 1-2 minutes
Subluxation of mandible beyond maxilla
Done during initial exam following consent, this exam will take 1-2 minutes
Neck extension
Done during initial exam following consent, this exam will take 1-2 minutes
- +5 more secondary outcomes
Study Arms (1)
Total body water measurement
Total body water will be measured using Bioelectrical Impedance Analysis (BIA).
Interventions
BIA will be used to determine total body water
Eligibility Criteria
Eligible participants will be approached for consent at our high risk maternal and infant program clinic on the day of their regularly scheduled appointment.
You may qualify if:
- Participants who give written informed consent
- Pregnant women in the third trimester of pregnancy
- Grade III obesity
- Patients who have prior diagnosis of OSA within the last one year, and non-compliant to treatment such as continuous positive airway pressure (CPAP), or dental appliance
- Patients suspected to have OSA based on screening questionnaire (see page 2, OSA-Diagnostic tools for further details)
You may not qualify if:
- Fluid overload states including renal disease, liver disease and congestive heart failure
- Prior history of vascular surgery in the lower limbs such as varicose vein surgery, vascular by-pass surgery or evidence of venous efficiency.
- Patients with metal implants in lower limbs or spine, due to possible interference with the leg impedance signals. 58
- Participants with diagnosed OSA treated with Continuous Positive Airway Pressure (CPAP).
- Patients requiring urgent sleep physician referral (within four weeks) due to serious medical conditions or safety critical-occupations according to the 2011 Canadian Thoracic Society (CTS) guideline 59 e.g. unstable ischemic heart disease, recent cerebrovascular disease.
- Implantable cardiac devices
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mount Sinai Hospital
Toronto, Ontario, M5G1X5, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mrinalini Balki, MD
MOUNT SINAI HOSPITAL
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 26, 2019
First Posted
December 5, 2019
Study Start
December 2, 2019
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
February 26, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share